[1] [1] PANG K, YANG Y, ZHAO P F, et al. Adding immune checkpoint blockade to neoadjuvant chemoradiation in locally advanced rectal cancer[J]. Br J Surg, 2022, 109(11): 1178-1179.

[2] [2] ESFAHANI K, ELKRIEF A, CALABRESE C, et al. Moving towards personalized treatments of immune-related adverse events[J]. Nat Rev Clin Oncol, 2020, 17(8): 504-515.

[3] [3] LERNER A, LEE A X, YAN H, et al. A multicentric, retrospective, real-world study on immune-related adverse events in patients with advanced non-small cell lung cancers treated with pembrolizumab monotherapy[J]. Clin Oncol (R Coll Radiol), 2024, 36(3): 193-199.

[4] [4] DOLLADILLE C, EDERHY S, SASSIER M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer[J]. JAMA Oncol. 2020; 6(6): 865-871.

[5] [5] WANG Y C, ZHOU S H, YANG F, et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis[J]. JAMA Oncol, 2019, 5(7): 1008-1019.

[7] [7] PASCHOU S A, STEFANAKI K, PSALTOPOULOU T, et al. How we treat endocrine complications of immune checkpoint inhibitors[J]. ESMO Open, 2021, 6(1): 100011.

[8] [8] CHANG L S, BARROSO-SOUSA R, TOLANEY S M, et al. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints[J]. Endocr Rev, 2019, 40(1): 17-65.

[9] [9] RAHMA O E, YOTHERS G, HONG T S, et al. Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial[J]. JAMA Oncol, 2021, 7(8): 1225-1230.

[10] [10] BANDO H, TSUKADA Y, INAMORI K, et al. Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer[J]. Clin Cancer Res, 2022, 28(6): 1136-1146.

[11] [11] NAIDOO J, PAGE D B, LI B T, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies[J]. Ann Oncol, 2015, 26(12): 2375-2391.

[12] [12] HAANEN J, OBEID M, SPAIN L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Ann Oncol, 2022, 33(12): 1217-1238.

[13] [13] CANO-CRUZ L G, BARRERA-VARGAS A, MATEOS-SORIA A, et al. Rheumatological adverse events of cancer therapy with immune checkpoint inhibitors[J]. Arch Med Res, 2022, 53(2): 113-121.

[14] [14] NGUY\U1EC5N T, MARIA A T J, LADHARI C, et al. Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO's adverse drug reactions database[J]. Ann Rheum Dis, 2022, 81(2): e32.

[15] [15] KRNER P T, MODY K, FARRAYE F A. Immune checkpoint inhibitor-related luminal GI adverse events[J]. Gastrointest Endosc, 2019, 90(6): 881-892.

[16] [16] THOMPSON J A, SCHNEIDER B J, BRAHMER J, et al. NCCN guidelines® insights: management of immunotherapy-related toxicities, version 2.2024[J]. J Natl Compr Canc Netw, 2024, 22(9): 582-592.

[17] [17] BRAHMER J R, LACCHETTI C, SCHNEIDER B J, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768.

[18] [18] CREE I A, BOOTON R, CANE P, et al. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation[J]. Histopathology, 2016, 69(2): 177-186.

[19] [19] SIMONAGGIO A, MICHOT J M, VOISIN A L, et al. Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer[J]. JAMA Oncol, 2019, 5(9): 1310-1317.

[20] [20] SAITO Y, TAKEKUMA Y, ASAHINA H, et al. Significantly delayed development of polyarthritis with active tenosynovitis after possible temporary neutropenic immune-related adverse events caused by atezolizumab treatment: a novel case report[J]. Case Rep Oncol Med, 2024, 2024: 1566299.

[21] [21] KITANO M, HONDA T, HIKITA E, et al. Delayed immunerelatet adverse events in long-responders of immunotherapy: a single-center experience[J]. Asia Pac J Clin Oncol, Aug 2024, 20(4): 463-471.